CA2536140A1 - Dosing schedule for erbb2 anticancer agents - Google Patents

Dosing schedule for erbb2 anticancer agents Download PDF

Info

Publication number
CA2536140A1
CA2536140A1 CA002536140A CA2536140A CA2536140A1 CA 2536140 A1 CA2536140 A1 CA 2536140A1 CA 002536140 A CA002536140 A CA 002536140A CA 2536140 A CA2536140 A CA 2536140A CA 2536140 A1 CA2536140 A1 CA 2536140A1
Authority
CA
Canada
Prior art keywords
methyl
inhibitor
yloxy
pyridin
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002536140A
Other languages
English (en)
French (fr)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2536140A1 publication Critical patent/CA2536140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002536140A 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents Abandoned CA2536140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
US60/495,919 2003-08-18
PCT/IB2004/002580 WO2005016347A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Publications (1)

Publication Number Publication Date
CA2536140A1 true CA2536140A1 (en) 2005-02-24

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002536140A Abandoned CA2536140A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Country Status (18)

Country Link
US (1) US20050119288A1 (https=)
EP (1) EP1658080A1 (https=)
JP (1) JP2007502807A (https=)
KR (2) KR20060037447A (https=)
CN (1) CN1838959A (https=)
AR (1) AR045268A1 (https=)
AU (1) AU2004264726A1 (https=)
BR (1) BRPI0413745A (https=)
CA (1) CA2536140A1 (https=)
CO (1) CO5670356A2 (https=)
IL (1) IL173127A0 (https=)
MX (1) MXPA06001989A (https=)
NO (1) NO20061252L (https=)
RU (1) RU2328287C2 (https=)
SG (1) SG135193A1 (https=)
TW (1) TW200522966A (https=)
WO (1) WO2005016347A1 (https=)
ZA (1) ZA200600517B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005016346A1 (en) * 2003-08-14 2005-02-24 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005028469A1 (en) 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
CN1972688B (zh) 2004-05-06 2012-06-27 沃尼尔·朗伯有限责任公司 4-苯胺基-喹唑啉-6-基-酰胺类化合物
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
CA2610661A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
EP1890677A4 (en) * 2005-06-16 2013-01-30 Myriad Genetics Inc PHARMACEUTICAL COMPOSITIONS AND THEIR USE
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CA2629714A1 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
ES2364901T3 (es) 2005-11-15 2011-09-16 Array Biopharma, Inc. Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
CA2647671A1 (en) * 2006-03-31 2007-11-01 Massachusetts Institute Of Technology Treatment of tumors expressing mutant egf receptors
AU2007234379A1 (en) * 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
CN103330694A (zh) 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
NZ580869A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Methods for treating cancer
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
WO2008124823A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Method of treating melanoma
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
CA2856803A1 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
EP3101115B1 (en) 2014-01-31 2020-10-21 Toppan Printing Co., Ltd. Biomolecule analysis kit and biomolecule analysis method
JP7057278B2 (ja) * 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
MX9707453A (es) * 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
HRP20021005A2 (en) * 2000-06-22 2004-02-29 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
GEP20063872B (en) * 2001-12-12 2006-07-10 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production
PL373848A1 (en) * 2001-12-12 2005-09-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
WO2004046101A2 (en) * 2002-11-20 2004-06-03 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
WO2004054585A1 (en) * 2002-12-18 2004-07-01 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
RU2006102125A (ru) 2007-09-27
ZA200600517B (en) 2007-02-28
SG135193A1 (en) 2007-09-28
RU2328287C2 (ru) 2008-07-10
AR045268A1 (es) 2005-10-19
IL173127A0 (en) 2006-06-11
MXPA06001989A (es) 2006-05-17
EP1658080A1 (en) 2006-05-24
KR20080014144A (ko) 2008-02-13
KR20060037447A (ko) 2006-05-03
AU2004264726A1 (en) 2005-02-24
BRPI0413745A (pt) 2006-10-24
CO5670356A2 (es) 2006-08-31
JP2007502807A (ja) 2007-02-15
US20050119288A1 (en) 2005-06-02
TW200522966A (en) 2005-07-16
CN1838959A (zh) 2006-09-27
NO20061252L (no) 2006-05-16
WO2005016347A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
US20050119288A1 (en) Dosing schedule for a novel anticancer agent
KR102871791B1 (ko) 병용 요법
US11096947B2 (en) Combination products with tyrosine kinase inhibitors and their use
CN109069504B (zh) 氨基噻唑化合物及其用途
TW202007396A (zh) Bcl-2抑制劑或Bcl-2/Bcl-xL抑制劑與BTK抑制劑的組合產品及其在預防和/或治療疾病中的用途
TW201831188A (zh) 涉及二芳基巨環化合物之組合療法
CA2544863A1 (en) Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN118369119A (zh) KRAS G12D抑制剂与泛ErbB家族抑制剂的组合疗法
JP2023075161A (ja) 癌の処置
KR20240170920A (ko) Sos1 억제제 및 egfr 억제제를 포함하는 병용 요법
KR20210038366A (ko) Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
JP2016106092A (ja) 組合せ
CN112237579B (zh) 药物组合及其用途
KR20250002214A (ko) Sos1 억제제 및 mek 억제제를 포함하는 병용 요법
HK40109894A (zh) Kras g12d抑制剂与泛erbb家族抑制剂的组合疗法
CN117615762A (zh) 组合疗法
WO2026090321A1 (en) Treatment of cancer with a kras inhibitor
HK1091745A (en) Dosing schedule for erbb2 anticancer agents
EA048458B1 (ru) Способы комбинированной терапии
HK40101229A (zh) 组合疗法
HK40035225A (en) Pharmaceutical combination and use thereof
HK40055040A (en) Combination therapies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued